Use of alternative or adjuvant pharmacologic treatment strategies in the prevention and treatment of Clostridium difficile infection  by Musgrave, Caitlin R. et al.
International Journal of Infectious Diseases 15 (2011) e438–e448Review
Use of alternative or adjuvant pharmacologic treatment strategies in the
prevention and treatment of Clostridium difﬁcile infection
Caitlin R. Musgrave a, P. Brandon Bookstaver b,*, S. Scott Sutton b, April D. Miller b
a South Carolina College of Pharmacy, University of South Carolina, Columbia, South Carolina, USA
bDepartment of Clinical Pharmacy and Outcomes Sciences, South Carolina College of Pharmacy, University of South Carolina, 715 Sumter Street, Columbia, SC 29208, USA
A R T I C L E I N F O
Article history:
Received 3 November 2010
Received in revised form 19 March 2011
Accepted 24 March 2011
Corresponding Editor: Craig Lee, Ottawa,
Canada.
Keywords:
Clostridium difﬁcile
Probiotics
Polymers
Immunotherapy
Rifamycin
Nitazoxanide
Fidaxomicin
S U M M A R Y
Infection with Clostridium difﬁcile is currently the leading cause of infectious diarrhea in hospitalized
patients, and recent surveillance data indicate that C. difﬁcile has surpassed methicillin-resistant
Staphylococcus aureus as the number one cause of hospital-acquired infections in some areas of the USA.
In addition, concern over C. difﬁcile has increased over the past decade due to the appearance of new
hypervirulent strains. Metronidazole and vancomycin have remained the treatments of choice for initial
therapy of primary infection with C. difﬁcile for the past 25 years, but the persistence of spores leads to a
recurrence of infection in an estimated 20–25% of patients. Patients who have one recurrent episode
have up to a 65% chance of having additional recurrence. While the judicious use of antimicrobials in
accordance with antibiotic stewardship guidelines remains the most effective method for the control of
C. difﬁcile, the high recurrence rate, increasing incidence, and changing epidemiology of C. difﬁcile has led
to an increased interest in the study of alternative strategies for the prevention and treatment of C.
difﬁcile disease. These alternative strategies attempt to eliminate C. difﬁcile spores, replenish the normal
gut ﬂora, reduce the C. difﬁcile toxin load in the bowel, or bolster the patient’s own immune response to
the C. difﬁcile toxins. To evaluate the available evidence on these alternative strategies, we conducted a
literature search of MEDLINE (1966–March 2011) and International Pharmaceutical Abstracts (1970–
March 2011). Available citations from these articles were also utilized. The aim of this review is to
summarize the available evidence for alternative treatment strategies for C. difﬁcile disease and to make
recommendations for their place in therapy.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Clostridium difﬁcile is a Gram-positive, anaerobic, spore-form-
ing, cytotoxin-producing bacillus transmitted via the fecal–oral
route.1 C. difﬁcile was ﬁrst linked to human disease in 1977 and has
increased in incidence to become the leading cause of infectious
diarrhea in hospitalized patients.2,3 The Centers for Disease Control
and Prevention (CDC) estimates the annual incidence of hospital-
ized cases of C. difﬁcile infection (CDI) to exceed 250 000, with a
mortality rate of 1–2.5% in infected persons and an estimated cost
to the health care system of over 3 billion dollars per year.1,4,5
Recent surveillance data indicate that C. difﬁcile has surpassed
methicillin-resistant Staphylococcus aureus (MRSA) as the number
one cause of hospital-acquired infections in some areas of the
USA.6
The increasing concern with C. difﬁcile seen over the past decade
has primarily been due to changing epidemiology. North America* Corresponding author. Tel.: +1 803 777 4786; fax: +1 803 777 2820.
E-mail address: bookstaver@sccp.sc.edu (P.B. Bookstaver).
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doi:10.1016/j.ijid.2011.03.017has seen CDI incidence increase ﬁve-fold in the community
dwelling populations. Incidence has also increased in Europe, most
noticeably the UK, the Netherlands, and France.7 In addition to the
increased number of cases, the severity has also increased.
Between 1997 and 2005, a nearly four-fold increase in C.
difﬁcile-associated mortality was observed in Canada.8 These
epidemiologic changes appear to be due in part to a new
hypervirulent, epidemic strain of C. difﬁcile, referred to as BI/
NAP1/027, which produces higher concentrations of toxins and
appears more resistant to treatment.7
The heightened interest in C. difﬁcile treatment is also related to
the high risk of C. difﬁcile infection in severely immunocompro-
mised HIV and cancer patients, as well as the appearance of C.
difﬁcile in patients treated with short courses of antibiotics for
traveler’s diarrhea or surgical prophylaxis.9,10 Therefore, the best
practice in all patients—high or low risk—is the judicious use of
antimicrobials for the prevention of CDI. Despite efforts to prevent
CDI, changing epidemiology and high rates of recurrence of CDI
demand an understanding of not only traditional treatment
options for infection, but also the evidence for alternativeses. Published by Elsevier Ltd. All rights reserved.
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treatments, we conducted a literature search of MEDLINE (1966–
March 2011) and International Pharmaceutical Abstracts (1970–
March 2011) and available citations from the reviewed literature.
2. Standard treatment of Clostridium difﬁcile infection
Initial treatment of CDI involves the discontinuation of
causative antimicrobial therapies.1,5 After discontinuation of
inciting antibiotics, current practice guidelines from the Society
for Healthcare Epidemiology of America and the Infectious
Diseases Society of America (SHEA/IDSA) recommend either
metronidazole or oral vancomycin as the treatments of choice.5
Oral metronidazole is recommended for initial episodes of mild-to-
moderate CDI (500 mg orally three times daily for 10–14 days) and
oral vancomycin (125 mg four times daily for 10–14 days) is
recommended for initial treatment of severe disease.5
The European Society of Clinical Microbiology and Infectious
Diseases treatment guidance document for CDI recommends
teicoplanin, a glycopeptide with similar activity to vancomycin,
at a dose of 100 mg twice daily as an additional oral treatment
option.11 Oral bacitracin (20 000–25 000 U four times daily for 7–
10 days) and fusidic acid (250–500 mg three times daily for 7–10
days) are considered less effective than the glycopeptides and
metronidazole and are therefore not recommended for use.
Teicoplanin, fusidic acid, and oral bacitracin are not available in
the USA.11,12
Because optimal treatment of CDI involves oral antibiotic
administration, treatment of a patient without oral access can be
challenging. Intravenous (IV) administration of metronidazole
diffuses from the serum of inﬂamed colon into the lumen and
undergoes hepatic recirculation, providing comparable concentra-
tions to oral administration.1 Vancomycin can also be adminis-
tered per rectum in the form of a retention enema or
intracolonically.13 Combination therapy with oral vancomycin
and IV metronidazole has also been suggested as initial therapy in
severe disease.5
3. Alternative agents and therapies
3.1. Assessing the need for alternative/adjuvant treatment strategies
Vancomycin and metronidazole have been used as effective
treatments for CDI for over 25 years, but they may further disrupt
and suppress the return of the healthy intestinal ﬂora and do not
reduce exposure to spores in the environment or positively alter
host risk factors. For these reasons, it is estimated that 20–25% of
patients who respond to initial treatment with metronidazole or
vancomycin will experience recurrence of C. difﬁcile, or reappear-
ance of clinical symptoms, typically within 2 weeks of completed
therapy.14,15
Approximately half of recurrences are due to relapse, while the
other half are due to reinfection. A relapse involves the same strain
of C. difﬁcile as the original infection and occurs when C. difﬁcile
spores remain in the intestine after CDI treatment.14,15 These
spores can easily proliferate and begin producing toxins again,
because the normal ﬂora of the intestine is not reestablished for
approximately 3 months.16
The SHEA/IDSA guidelines recommend that a patient
experiencing their ﬁrst recurrence of C. difﬁcile be treated with
the same antibiotic as was used for the initial episode; however,
patients who have a single recurrence have up to a 24% chance of
having repeat recurrence, and risk increases up to 65% when a
patient has had more than two prior episodes of CDI. Treatment
with vancomycin instead of metronidazole or vice versa does not
reduce this likelihood.16,17Due to the high recurrence rate, as well as increasing incidence
and fatality rate of CDI since the year 2000, there has been
increased interest in the study of alternative and adjuvant
strategies for the prevention and treatment of CDI.4 These
strategies attempt to eliminate C. difﬁcile spores, replenish normal
gut ﬂora, reduce C. difﬁcile toxin load in the bowel, or bolster the
patient’s own immune response to C. difﬁcile toxins. Table 1
provides a summary of pharmacologic agents discussed in this
review.
3.2. Alternative vancomycin dosing strategies
Alternative dosing strategies that have been successfully used
in the treatment of chronically recurring CDI are tapered dose
vancomycin, which involves a gradual lowering of the vancomycin
dose over time, and pulsed dose vancomycin, which involves short,
intermittent courses. In addition, the use of adjunctive intracolonic
vancomycin has been studied for the treatment of severe CDI.
In 1985, Tedesco et al. reported a case series of 22 patients
whose recurrent CDI was treated using these strategies: patients
were ﬁrst treated with a 6-week tapered regimen of vancomycin
(125 mg every 6 h for 1 week, then 125 mg every 12 h for 1 week,
then 125 mg daily for 1 week), followed by a pulsed dose regimen
(125 mg every other day for 1 week, then 125 mg every 3 days for 2
weeks). No recurrences were reported after 6 months.18
In 2002, McFarland et al. reported a case series of 163 patients
with recurrent CDI who were treated with various dosing regimens
of vancomycin. Vancomycin tapered dosing (doses decreased
stepwise from 500 mg–3 g per day down to 125–750 mg per day
over approximately 21 days) resulted in a 31% recurrence rate, and
pulsed dosing of vancomycin (125–500 mg as a single daily dose
every 2–3 days over approximately 27 days) resulted in a 14%
recurrence rate, compared to 43–54% recurrence rates with
standard vancomycin 10-day regimens.17
Targeted antibiotic therapy eradicates C. difﬁcile colonies but
has no effect on spores, leading to recurrence of infection. It is
hypothesized that pulsed and tapered dosing regimens allow C.
difﬁcile spores to germinate and then eliminate the cells, while also
supporting re-establishment of normal ﬂora in the intestines.17
One major concern with pulsed and tapered regimens is the
development of vancomycin-resistant Enterococcus (VRE), given
the protracted exposure to vancomycin.15
Though there are no randomized controlled trials evaluating
these dosing regimens, 2010 SHEA/IDSA guidelines recommend for
second recurrence of CDI a usual dosage of 125 mg four times daily
for 10–14 days followed by 125 mg twice daily for 1 week, 125 mg
once daily for 1 week, and then 125 mg every 2 or 3 days for 2 to 8
weeks.5 At this time, the use of tapered or pulsed dose vancomycin
should be considered for treatment of second or later recurrences
of CDI.
The adjunctive intracolonic administration of vancomycin to
patients with C. difﬁcile colitis has been studied in an attempt to
achieve higher concentrations of drug within the colon than may
be achieved by oral administration of vancomycin or metronida-
zole alone.13 Intracolonic vancomycin therapy involves adminis-
tration of an IV solution of vancomycin via intracolonic bolus (for
example, a 2 g bolus followed by 100 mg after each watery stool in
addition to 125 mg of oral vancomycin four times daily) or via
rectal retention enema (for example, individual doses of 500 mg in
1 l of normal saline).19 Administration via retention enema may be
a more desirable option due to the risk of perforation with the
insertion of catheters into the colon for intracolonic bolus. A
literature review by Apisarnthanarak et al. estimates a success rate
for intracolonic vancomycin of 57–75%. Patients receiving intra-
colonic vancomycin in case reports or case series have not
experienced recurrent disease, required surgical intervention, or
Table 1
Summary of alternative or adjuvant treatment options for Clostridium difﬁcile infection
Agent Dosing Mechanism of action Role in treatment Cautions
Alternative dosing regimens
of vancomycin
Tapered dose 125mg every 6 h10–14 days, then
125mg every 12 h7 days, then
125mg every 24 h7 days
Normal antibiotic therapy has no effect
on spores; tapered or pulsed dosing
allows spores to germinate before
eliminating the cells
Second or greater recurrence of CDI Do not administer with cholestyr-
amine, colestipol or other anion-ex-
change resins, which will bind
vancomycin
Pulsed dose 125mg every other day7 days, then
125mg every 3 days x 14 days
See ‘tapered dose’ See ‘tapered dose’ See ‘tapered dose’
Intracolonic
administration
Intracolonic 2 g bolus, then 100mg
after eachwatery stool. Rectal retention
enema: 500mg in 1 l of normal saline
per dose
Attempts to achieve higher concentra-
tions of vancomycin within the colon
than may be achieved by oral adminis-
tration
Patients who cannot take vancomycin
by mouth; adjunctive to oral treatment
in severe or recurrent disease
Intracolonic bolus may lead to a risk of
perforation with insertion of catheters
into the colon
Probiotics and prebiotics
Probiotics (lactobacilli,
biﬁdobacteria,
Saccharomyces boulardii)
Studied dosages typically range from
107 to 1011 CFU per day, which are
comparable doses to those found in
available over-the-counter probiotic
preparations
Inhibit the growth of C. difﬁcile via
production of antimicrobials and acids
to decrease the pH of the intestine;
protect the endothelium; have positive
immunologic effects
Prevention of CDI or as an adjunct to
treatment in otherwise healthy
patients
Immunocompromised HIV or cancer
patients are at an increased risk for
translocation of the organism, leading
to bacteremia or fungemia
Prebiotics Dosage levels differ based on type of
prebiotic ﬁber; ranges from 3 g/day for
short-chain fructooligosaccharides to 8
g/day for mixed short- and long-chain
inulin
Non-digestible oligosaccharides; die-
tary ﬁbers that improve intestinal
microﬂora
See ‘probiotics’ See ‘probiotics’
Fecal transplantation
Patient preparation:
Vancomycin 250mg PO every 8 h4
days; omeprazole 20 mg2 doses; (+/
 ) polyethylene glycol
Stool sample preparation:
Blend 30g stool sample and 50–70ml
sterile normal saline for 2–4min, ﬁlter
twice with coffee ﬁlter
Administration:
Via rectal retention enema, colono-
scope, or nasogastric, nasoduodenal,
or nasojejunal
Replacement of the healthy intestinal
ﬂora will suppress the growth of C.
difﬁcile
Treatment of third or greater recur-
rence of CDI
Ensure donors are screened for conta-
gious infectious agents before perform-
ing transplant
Colonization with
nontoxigenic C. difﬁcile
Dosing is based on the speciﬁc strain of
nontoxigenic C. difﬁcile administered
(i.e., 106 CFU)
Compete with toxigenic strains for
nutrients and adherence in the bowel
If developed, may be useful for preven-
tion of recurrence of CDI
May be ineffective if nontoxigenic
strain is susceptible to the antibiotic
used for treatment of CDI
Whole bowel irrigation
Polyethylene glycol Given until patient produces profuse,
clear liquid stools: 17g of powder
mixed in 8 oz of clear liquid adminis-
tered every 10min until 2 l are con-
sumed
May reduce the bacterial, toxin, and
spore load from the intestines by
producing a rapid intestinal transit
time and diluting intestinal bacteria
For adjunctive use prior to fecal trans-
plantation or in patients who have
experienced multiple recurrences of
CDI
Will cause an increase in abdominal
bloating, cramping, diarrhea, ﬂatulence
and nausea
Toxin binding adsorbents
Ion-exchange resins Cholestyramine: 4 g three to four times
a day1–2 weeks
Colestipol: 10 g four times a day5
days or 5 g twice a day1–2 weeks
Exchange a chloride ion for C. difﬁcile
toxin to form a non-absorbable com-
plex with the toxin in the intestinal
tract
For refractory cases of CDI, or in
patients for whom a negative toxin
assay is necessary for discharge
Due to binding of vancomycin and
potential binding of metronidazole, do
not administer within 2–3 h of either
antibiotic
Non-antibiotic polymer Tolevamer 3 to 6g daily (not available) A toxin-binding polymer developed to
bind C. difﬁcile toxins in the intestinal
tract
If developed, non-antibiotic polymers
would be useful as an adjunctive agent
to standard therapies
Development of tolevamer has been
halted secondary to negative results in
phase III clinical studies
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Table 1 (Continued )
Agent Dosing Mechanism of action Role in treatment Cautions
Oral beta-lactamases
1 or 6 mg/kg in mice Orally administered beta-lactamase en-
zyme would maintain colonization
resistance of the intestinal ﬂora by
inactivating any parenterally adminis-
tered beta-lactam given to treat an
infection outside the GI tract
Human models may prove this to be a
potential prevention strategy in
patients who are at high risk for the
development of CDI
Must not be used with orally adminis-
tered antibiotics, and will only be
effective for prevention of C. difﬁcile
caused by beta-lactam antibiotics; not
yet tested in humans
Immunotherapy
Intravenous immunoglobulin 150–400 mg/kg for 1–6 doses Attempt to increase low serum anti-
body levels of C. difﬁcile toxin A, which
can predispose patients to CDI
For patients who have failed other
therapies or in patients in whom
surgery is being considered
Further clinical studies are needed
before recommendations can be made
regarding its use
Monoclonal antibodies
against C. difﬁcile
Intravenous infusion of 10 mg/kg of
each monoclonal antibody
Neutralize the toxins and boost the
ability of the immune system to re-
spond to infection
For patients with severe or recurrent
CDI in combination withmetronidazole
or vancomycin
Further development and clinical eval-
uation of monoclonal antibodies is
necessary before they are routinely
used
Vaccination with inactivated
toxoids A and B
Passive immunization by increasing
circulating antibody levels against C.
difﬁcile toxins and reducing rate of
recurrence
Upon development, may be useful for
CDI prevention in high-risk individuals
Older adults who would beneﬁt most
from vaccination may have suboptimal
response
Alternative antimicrobials
Bismuth subsalicylate 100mg of bismuth subsalicylate added
to 10ml of ﬂuid to produce a soluble
bismuth product
An over-the-counter product with in
vitro antibacterial activity against C.
difﬁcile at concentrations achievable
within the GI tract
No current in vivo evidence to support
use as an adjunctive option in the
prevention or treatment of C. difﬁcile
General ADEs include darkening of the
tongue or tinnitus; avoid use of salicy-
lates in pediatric patients
Rifampin 300–600mg every 12 h in combination
with vancomycin treatment
A rifamycin antibiotic with high in vitro
activity against C. difﬁcile
Not recommended for use Non-signiﬁcant increase in mortality in
single study; concern for drug–drug
interactions and development of resis-
tance
Rifaximin (Xifaxan1) 400–800mg daily in 2–3 divided
doses2 weeks
A rifamycin antibiotic with high in vitro
activity against C. difﬁcile; neither
absorbed by the GI tract nor inactivated
by gastric juices; exerts its action
entirely within the intestinal lumen
For patients with refractory or recur-
rent CDI
Further clinical studies necessary to
conﬁrm efﬁcacy; caution recom-
mended due to the chance for increased
MICs of isolates during treatment;
general ADEs include peripheral edema,
dizziness, fatigue, ascites and nausea
Nitazoxanide 500mg every 12 h A nitrothiazolide which blocks anaero-
bic metabolism of eukaryocytes and
inhibits C. difﬁcile in vitro at low
concentrations
For initial treatment of severe C. difﬁcile
or for recurrent, refractory disease
Further studies are needed to conﬁrm
efﬁcacy and compare to current treat-
ment strategies; general ADEs are mild
Tigecycline 100mg IV daily1 dose, 50mg IV every
12 h
A glycylcycline antibiotic found to be
highly active in vitro against some C.
difﬁcile strains; reaches fecal concen-
trations high enough to reduce intesti-
nal microﬂora without inducing C.
difﬁcile or cytotoxin production
For initial treatment of other Gram-
positive infections in patients who may
be at high risk for development of CDI
Further clinical studies are necessary to
determine the true therapeutic role;
general ADEs are GI complaints
Linezolid 600mg IV/PO every 12 h (standard
dosing, speciﬁc dosing for CDI un-
known)
An oxazolidinonewhich is highly active
in vitro against some C. difﬁcile strains
and has a high percentage excreted
unchanged in the stool
Despite promising in vitro activity, in
vivo results are not conclusive enough
to recommend use at this time
Further clinical studies are necessary to
determine the true therapeutic role;
ADEs include diarrhea
Unapproved antimicrobials
Ramoplanin 200 or 400mg administered twice daily
for 10 days
An antimicrobial compound that inhi-
bits cell wall synthesis by acting at the
level of lipid intermediate formation
against C. difﬁcile
May offer an alternative for the initial
treatment of CDI upon approval
Further clinical studies are necessary to
determine the true therapeutic role;
general ADEs include GI complaints
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Intracolonic vancomycin may be a useful treatment option not
only in those patients who cannot take vancomycin orally, but also
as an adjunctive treatment to standard therapy in patients with
severe or recurrent disease.
3.3. Probiotics
The use of probiotics for the prevention and treatment of CDI
has been an area of growing interest over the past decade.
Probiotics have multiple mechanisms of action against pathogenic
C. difﬁcile. Some probiotics (speciﬁcally lactobacilli and biﬁdobac-
teria) have been shown to cause a phenomenon known as
‘colonization resistance’, in which the growth of C. difﬁcile is
inhibited via production of antimicrobials and acids to decrease the
pH of the intestine. Probiotics also protect the epithelium as a
result of increased mucin production in the colon, and can cause an
increased absorption of water via chloride channels to reduce
diarrhea. Probiotics also have immunologic effects, decreasing
inﬂammation or increasing expression of immunoglobulins
against C. difﬁcile toxin A. Some probiotics (speciﬁcally Saccharo-
myces boulardii) have been shown to prevent the C. difﬁcile toxins A
and B from binding in the intestine.20 Probiotics are dosed based on
colony-forming units (CFU), and studied dosages typically range
from 107 to 1011 CFU per day. These dosages are comparable to
those found in over-the-counter probiotics such as Culturelle1
(Lactobacillus rhamnosus GG), Align1 (Biﬁdobacterium infantis), or
Florastor1 (S. boulardii). Some products may list the dosage in
terms of milligrams (Align1, 4 mg; Florastor, 250 mg), but this is
typically listed along with the number of CFU contained in the
product.
Probiotics have been shown to be safe in most patient
populations, and cause few drug interactions.20,21 There have
been reports of serious adverse events, including bacteremia or
fungemia acquired by translocation of the organism from the
gastrointestinal tract to other areas of the body.22 Severely
immunocompromised HIV or cancer patients are at highest risk
for translocation due to depletion of CD4 cells in the gut or direct
toxic effects of chemotherapy agents, respectively.9,10 Use of
probiotics in this patient population should be done with caution.
Another concern with the use of probiotics is the lack of
standardization, regulation, and quality control of these over-
the-counter supplements.23,24
In 2006, a meta-analysis reported that the probiotics S.
boulardii, L. rhamnosus GG, and mixtures of probiotics were useful
in the prevention of CDI, signiﬁcantly reducing development of the
disease. The meta-analysis also found S. boulardii to be effective for
the treatment and prevention of CDI. When used as adjuvant
therapy for secondary prophylaxis against CDI, S. boulardii
signiﬁcantly decreased the rate of relapse. L. rhamnosus GG and
Lactobacillus plantarum 299 v were not found to produce statisti-
cally signiﬁcant reductions in the rate of relapse.25
Trials of probiotics as prophylaxis against CDI in hospitalized
patients have shown that combinations of probiotics may be more
effective. The combination of Lactobacillus acidophilus, Biﬁdobac-
terium biﬁdum, and Lactobacillus bulgaricus signiﬁcantly decreased
the rate of occurrence of CDI, while a combination of Lactobacillus
casei DN-114 001, L. bulgaricus, and Streptococcus thermophilus has
been shown to prevent reoccurrence and signiﬁcantly decrease the
rate of occurrence of CDI.26
In 2008, a Cochrane Review reported studies suggesting a
beneﬁt in the treatment of recurrent infection, but did not
recommend the use of probiotics for treatment or prevention of
initial CDI.27
The use of ‘designer probiotics’ in CDI has also been explored.
Lactococcus lactis and Lactobacillus salivarius produce bacteriocins,
C.R. Musgrave et al. / International Journal of Infectious Diseases 15 (2011) e438–e448 e443toxins that can inhibit the growth of C. difﬁcile. Gastric acidity
negatively affects the stability of the bacteriocin produced by
Lactococcus lactis, so the genes required for production of this
bacteriocin have been cloned and expressed in L. salivarius to
prevent degradation during digestion. Other ‘designer probiotics’
have been engineered to contain receptors to the C. difﬁcile toxin.
These receptors bind the toxin, preventing it from causing damage
and allowing it to be safely eliminated. Trials of these recombinant
probiotics in animal models are ongoing, but they have not yet
been tested in human subjects.28,29
Probiotics are not recommended in the 2010 SHEA/IDSA
treatment guidelines.5 There are numerous clinical trials under-
way assessing the efﬁcacy of these agents, and the results of these
studies will help determine the future use of probiotics in CDI. At
this time, the use of probiotics could be considered for the
prevention of CDI or as adjunctive treatment in otherwise healthy
patients, considering the risk of translocation and secondary
infection in severely immunocompromised patients.
3.4. Bacteriotherapy by way of fecal transplantation
When treatment with antibiotics fails to clear CDI due to lack of
restoration of healthy intestinal ﬂora, replacement of the
gastrointestinal contents with healthy fecal material could be
considered the ‘ultimate probiotic’.30
Patients considered for stool transplantation typically have a
laboratory-conﬁrmed diagnosis of C. difﬁcile colitis with two or
more documented relapses after initial antimicrobial treatment.
Preferred stool donors are typically individuals who have intimate
contact with the patient in an attempt to reinstate gastrointestinal
microbiota similar to the patient’s original ﬂora. Donors must be
screened for infectious agents, including serologic testing for
hepatitis A, B, and C; HIV-1 and HIV-2; syphilis; and stool cultures
for enteric bacterial pathogens, ova, and parasites.31,32
The stool transplant recipient is often treated with 4 days of
vancomycin (250 mg every 8 h) to reduce the C. difﬁcile load, as
well as two doses of omeprazole (20 mg) to decrease gastric acid
production and create a receptive environment for the new
bacteria to colonize. Some colonic preparation regimens also
include administration of polyethylene glycol in an attempt to
eliminate C. difﬁcile organisms and spores before administration of
transplanted stool. Preparation of the donor stool sample before
transplantation typically involves obtaining the sample, adding
sterile normal saline and homogenizing in a blender, and ﬁltering
the suspension with a paper coffee ﬁlter.31,32
The prepared stool sample may be instilled into the lower or
upper end of the gastrointestinal tract. To date, most reported
cases have received fecal transplantation through the rectum via
retention enema or colonoscope, although instillation into the
upper gastrointestinal tract via a nasogastric, nasoduodenal, or
nasojejunal tube appears to have a low risk of complications,
requires a small volume of stool, and may require only one
treatment.31,32
The use of fecal transplantation has been documented in the
literature since 1958, and though treatment guidelines still do not
recommend fecal transplantation due to insufﬁcient evidence, the
available evidence of fecal bacteriotherapy for recurrent CDI is
promising, with some studies reporting over 90% success rates.5,33
Particular interest and success with this treatment option has
been seen in Canada, where the new hypervirulent, epidemic
strain of C. difﬁcile has led to a three-fold increase in mortality
since the early 1990 s; and success rates have led to increased
interest in the USA as well.8 A recently published retrospective
case series reported a response rate of 100% in 12 patients with
recurrent CDI treated with transplantation of donor stool via
colonoscopy.34While fecal transplantation appears to be extremely successful
and well tolerated assuming accurate and extensive screening of
donors, the procedure does lack a certain aesthetic appeal, which
could result in a patient’s unwillingness to accept treatment.
However, after recurrent bouts of C. difﬁcile-associated disease,
most patients appear receptive to the procedure.31 In the willing
patient who has experienced multiple episodes of CDI refractory to
current therapies, fecal transplantation could be used as an
alternative treatment strategy.
3.5. Colonization with nontoxigenic Clostridium difﬁcile
Pathogenic strains of C. difﬁcile produce toxin A, toxin B, and
binary toxin. Nontoxigenic strains of C. difﬁcile, which lack the
genes to produce toxins and do not appear to cause human disease,
have been found in studies of asymptomatic patients.35 It is
assumed that nontoxigenic strains compete with toxigenic strains
for nutrients and adherence in the bowel, thus preventing infection
or recurrence of infection. In 1987, Seal et al. reported that oral
administration of nontoxigenic strains of C. difﬁcile led to remission
of infection in two patients.36 A 1998 study by Kyne et al. suggested
that patients who had been asymptomatically colonized with C.
difﬁcile developed enough serum IgG antibody response to toxin A
to prevent clinical symptoms.37 Nontoxigenic colonization of both
hamsters and pigs has been successful in preventing subsequent
colonization with a toxigenic strain of C. difﬁcile upon chal-
lenge.35,38 Dosages of nontoxigenic C. difﬁcile are typically based on
the speciﬁc strain administered (e.g., 1  106 spores/day).35 Due to
the promising results in animal models, a phase I clinical trial for
nontoxigenic C. difﬁcile (NTCD) is underway to determine the
safety and tolerability of oral NTCD in healthy adults.39
3.6. Whole bowel irrigation
Polyethylene glycol is often used prior to fecal transplantation
in hopes of reducing bacterial and toxin load, as well as providing a
suitable environment for transplantation of healthy fecal matter. In
1996, Liacouras and Piccoli reported the success of whole bowel
irrigation with polyethylene glycol as adjuvant therapy in two
pediatric patients with refractory C. difﬁcile disease.40 In these
patients, the polyethylene glycol was given until the patient
produced profuse, clear liquid stools (which typically requires a
dosing regimen of 17 g of powder in 8 ounces of clear liquid given
every 10 min until 2 l are consumed). The polyethylene glycol was
followed by a 3-week course of oral vancomycin plus Lactobacillus;
therefore, it is difﬁcult to determine if the whole bowel irrigation
was essential to therapeutic success. However, the authors suggest
that whole bowel irrigation clears active C. difﬁcile organisms,
toxins, and spores from the intestine. The possible mechanism of
action of polyethylene glycol in C. difﬁcile is unknown, but theories
include that polyethylene glycol results in rapid intestinal transit
time and dilution of intestinal bacteria.41 It does not appear that
polyethylene glycol has any antibacterial effect.41 It is important to
keep in mind that polyethylene glycol will cause abdominal
bloating, cramping, and diarrhea. There is not extensive evidence
in the literature for the use or success of whole bowel irrigation;
therefore, at this time whole bowel irrigation should be reserved
for adjuvant use prior to fecal transplantation or in patients who
have experienced multiple recurrences of CDI.
3.7. Toxin-binding adsorbents
3.7.1. Ion-exchange resins
Cholestyramine and colestipol have been studied for use in CDI
due to their ability to exchange chloride ions for C. difﬁcile toxin to
form a non-absorbable complex with the toxin in the intestine.42
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the late 1970 s, even prior to identiﬁcation of C. difﬁcile as the
causative pathogen.43 One early study showed successful binding
of C. difﬁcile toxin by both agents in vitro and also demonstrated
efﬁcacy of cholestyramine at delaying death in hamster models.44
Colestipol was studied in a randomized controlled trial of 38
patients at a dose of 10 g four times daily for 5 days, but was shown
to be no better than placebo with an initial cure rate of 25%.45
Further studies of colestipol administered in conjunction with
vancomycin were inconclusive. Subsequently, case studies report-
ing success of extended course cholestyramine in patients with
recurrent or relapsing C. difﬁcile colitis were published.46–48
While ion-exchange resins are generally safe, with the major
side effect being constipation, a potential contraindication to their
use in CDI is their binding of oral vancomycin. Ion-exchange resins
reduce fecal concentrations of vancomycin up to 80%.42,44,49 SHEA/
IDSA guidelines indicate that this interaction is a contraindication
to the use of ion-exchange resins, but some researchers support
their use when separated by 2–3 h from the vancomycin doses.1,5
There have been conﬂicting reports of whether metronidazole is
bound by cholestyramine. In vitro studies have failed to show an
interaction, but other studies have demonstrated an approximate
20% reduction in metronidazole bioavailability.49 Without conclu-
sive data, the administration of ion-binding resins and metronida-
zole should be separated by at least 2 h.50
Despite binding of vancomycin and potentially metronidazole,
ion-exchange resins have a mild adverse effect potential and are
inexpensive, making them attractive adjunctive treatment options
to standard therapy for CDI. Current suggestions for the use of ion-
exchange resins include colestipol 5 g every 12 h or cholestyr-
amine 4 g three to four times daily for 1 to 2 weeks, in conjunction
with metronidazole or vancomycin, administered at least 2 h after
the oral antibiotic dose.1,5 Toxin-binding capacity of these agents is
a known commodity, but the risk of binding orally administered
therapies often precludes their routine use as an adjunctive
therapy. A potentially novel use of these agents may be in patients
requiring a negative toxin to be eligible for discharge.
3.7.2. Non-antibiotic polymer
Tolevamer is a toxin-binding polymer developed to bind C.
difﬁcile toxins in the intestinal tract at doses of 3–6 g daily.42
Tolevamer offers inherent advantages over standard therapies as it
has no antibiotic properties, does not further suppress or harm
normal gut ﬂora, and would not result in the development of
resistant strains.51 As opposed to ion-exchange resins, tolevamer
does not appear to bind metronidazole or vancomycin. Initial
studies resulted in severe hypokalemia, prompting product
reformulation to a potassium sodium salt (ExodifTM) by Genzyme,
which was found to be safe and effective in phase I trials.52
Early phase II studies of tolevamer reported similar outcomes
compared to standard therapy in mild-to-moderate CDI, as well as
a trend towards lower recurrence rates. These results were
confounded by high dropout rates in the tolevamer groups ranging
from 23% to 50%. Phase III trials of tolevamer published in 2009
reported that tolevamer was not successful in reducing the
duration or magnitude of C. difﬁcile toxin activity, and at this time
further development of tolevamer has been terminated.42,53 If
development of non-antibiotic polymers does resume, they would
most likely serve an adjunctive role to standard therapies for C.
difﬁcile treatment.
3.8. Oral beta-lactamases
Exposure to antibiotics remains the most important risk factor
for the development of CDI. In many cases, the inciting antibiotic is
being used to treat a source of infection that lies outside of thegastrointestinal tract; therefore, there is no need for antimicrobial
activity within the intestines. It has been hypothesized that
administration of an oral beta-lactamase in conjunction with a
parenterally administered beta-lactam antibiotic could be a useful
strategy for prevention of development of CDI. Theoretically, beta-
lactam antibiotics reaching the intestine during parenteral
administration would be inactivated by the orally administered
beta-lactamase, thus preventing destruction of normal gastric ﬂora
and subsequent colonization with C. difﬁcile. Stiefel et al. have
demonstrated that administration of a proteolysis-resistant beta-
lactamase could degrade beta-lactam antibiotics—thus maintain-
ing the colonization resistance of intestinal ﬂora—within the small
intestine in animal models.54,55 Human models may prove the use
of oral beta-lactamase enzymes to be a potential preventative
strategy in patients at high risk for development of CDI requiring
parenteral beta-lactam therapy.
3.9. Immunotherapy
Immunotherapy has become an area of increasing interest with
the emergence of hypervirulent strains of C. difﬁcile. Immunother-
apy for CDI involves administration of antibodies against
clostridial toxins via transfer of active immunity with intravenous
immunoglobulins (IVIG) or through monoclonal antibody therapy.
3.9.1. Immunoglobulins
IVIG have been studied in C. difﬁcile disease in an attempt to
increase low serum antibody levels to C. difﬁcile toxin A, as these
low levels have been shown to predispose patients to the
development of CDI.37 Though the true mechanism of IVIG
entering the colon and binding C. difﬁcile toxins is not understood,
it is thought that immunoglobulins may be able to cross the colonic
membrane due to the inﬂammation caused by C. difﬁcile
toxin.56IVIG was ﬁrst used for C. difﬁcile colitis in 1991 by Leung
et al. in the treatment of pediatric patients, all of whom achieved a
full resolution of symptoms.57 Unfortunately, since then, studies
on the use of immunoglobulins for C. difﬁcile have been limited. A
systematic review of the literature in 2009 by O’Horo et al.58
revealed only four retrospective studies and ﬁve case reports on
the use of IVIG for the treatment of C. difﬁcile infection, as well as
one study using oral immunoglobulin. Only one study was
controlled, which failed to show a beneﬁt of IVIG compared to
standard treatment in severe CDI.58 A retrospective review of 21
patients with C. difﬁcile colitis conducted by Abougergi et al. in
2010 found that not all patients beneﬁted from treatment with
IVIG. Only nine patients survived their illness and were discharged
from the hospital, while 12 patients died during hospitalization.59
Doses of IVIG range from 150 to 400 mg per kg per dose.60 Often,
only one dose of IVIG is necessary, but repeat doses have been
documented in patients who experience further recurrence of C.
difﬁcile.57–59
The available literature does indicate a possible beneﬁt with
IVIG in severe CDI and it may be considered in refractory and
recurrent CDI, given the relatively low immune response common
among patient with recurrent infections. Drug-induced aseptic
meningitis should be considered as a possible adverse event from
IVIG therapy. IVIG may be a useful adjunctive treatment option in
those who have failed initial therapies or in seriously ill patients in
whom surgery is being considered.
3.9.2. Monoclonal antibodies
Monoclonal antibodies targeted against C. difﬁcile toxins have
been developed in an attempt to neutralize toxins and enhance the
immune response. A randomized, double-blind, placebo-con-
trolled study of 200 patients found that the addition of 10 mg
per kg of two monoclonal antibodies against C. difﬁcile toxins A and
C.R. Musgrave et al. / International Journal of Infectious Diseases 15 (2011) e438–e448 e445B to a standard antibiotic agent (vancomycin and metronidazole)
signiﬁcantly reduced recurrence of CDI compared to those who
received only standard therapy (7% vs. 25%, respectively).61
A phase II randomized, double-blind, placebo-controlled trial
evaluating C. difﬁcile anti-toxin A serum antibody was conducted to
determine the correlation between C. difﬁcile anti-toxin A serum
antibodies and protection against symptomatic CDI as well as
disease recurrence. The study found no signiﬁcant difference in the
rate of recurrence between the two groups, although time to
recurrence was shorter in the antibody group. The study did ﬁnd
that recurrence of CDI was associated with lower concentrations of
antibodies against anti-toxin A and B, as well as with resistant
strains of C. difﬁcile.62 Merck has entered a licensing agreement for
this monoclonal antibody combination (CDA-1 and CDB-1, also
known as MDX-066/MDX-1388 or MBL-CDA1/MBL-CDB1) and will
continue the development.63
Though not yet commercially available, monoclonal antibody
preparations against C. difﬁcile toxins may be useful in patients
with severe or recurrent CDI in combination with metronidazole or
vancomycin.
3.9.3. Vaccination
Passive and active immunization with a C. difﬁcile toxoid vaccine
are being tested in a phase II, randomized, secondary prevention
trial. The vaccination contains inactivated toxoids A and B and is
immunogenic and well-tolerated in healthy volunteers.64 Patients
who would seemingly beneﬁt the most from vaccination are older
adults who may have a suboptimal immune response to vaccination.
Sanoﬁ-Aventis is currently conducting a study comparing the rate of
CDI development in groups receiving ACAM-CDIFFTMvaccine versus
placebo: the ﬁrst stage of the study is designed to test four different
formulations of the vaccine (low-dose or high-dose with or without
adjuvant), while the second stage will determine the optimal
vaccination schedule. DNA vaccines to C. difﬁcile toxins have also
been developed and have been found to produce high titer
antibodies and protect mice from death; however, these vaccines
have not yet been studied in humans.65 Results of human trials will
help determine the place in therapy for this promising vaccination
strategy.
3.10. Alternative antimicrobials
3.10.1. Bismuth subsalicylate
Bismuth subsalicylate, the active ingredient in Pepto-Bismol1
(Procter & Gamble, Cincinnati, OH, USA), is known to have
antibacterial activity at concentrations that are achievable within
the gastrointestinal tract. Studies of the in vitro activity of bismuth
subsalicylate have shown sensitivity of C. difﬁcile to this widely
available over-the-counter product. In 1990, Cornick et al.
published a study demonstrating in vitro activity of bismuth
subsalicylate against C. difﬁcile, and Gorbach et al. determined that
bismuth subsalicylate did not have adverse effects on normal fecal
ﬂora.66,67 Chang et al. found that bismuth subsalicylate was useful
in the treatment of C. difﬁcile in hamsters.68 A 2004 study by
Mahony et al. further demonstrated the in vitro activity of bismuth
subsalicylate (100 mg dissolved in 10 ml of various ﬂuids) against
C. difﬁcile.69 General adverse effects of bismuth subsalicylate are
mild and may include darkening of the tongue and stool or tinnitus.
Clinical investigation of bismuth subsalicylate may be worth
pursuing, as this product may be an option as an adjunct in the
treatment of C. difﬁcile or as a secondary prophylaxis during gut
ﬂora restoration following antibiotic therapy.
3.10.2. Rifamycin antibiotics
Agents from the rifamycin class of antibiotics, including rifampin
and rifaximin (Xifaxan1, Salix Pharmaceuticals, Morrisville, NC,USA), have been studied as potential agents for recurrent CDI due to
their potent in vitro activity.70 In 2008, Garey et al. reviewed the
literature relating to rifamycin antibiotics for use in CDI and found
that while there is extensive evidence that members of this class of
antibiotics have in vitro activity against C. difﬁcile, there were only
six published clinical reports investigating their use clinically.70 The
evidence for rifampin included a case study indicating resolution of
fever and diarrhea after administration, as well as a case series of
seven patients who normalized within 3 days of rifampin initiation,
with the most common dosage regimens of rifampin for C. difﬁcile
being 300–600 mg every 12 h in combination with vancomycin
treatment.71,72 A prospective, single-blinded study comparing
metronidazole to metronidazole plus rifampin for ﬁrst episodes of
CDI found no clinical beneﬁt in the rifampin group, and rifampin
treatment was associated with a non-signiﬁcant increase in
mortality.73 There is also a great concern with signiﬁcant drug–
drug interactions and the development of rifampin resistance.70
Of the rifamycins, rifaximin is the most appealing for use in the
treatment of CDI. The agent is neither absorbed by the
gastrointestinal tract nor inactivated by gastric juices, and it
exerts its action entirely within the intestinal lumen.74 While C.
difﬁcile strains have been shown to develop resistance to rifaximin
when only low concentrations of the antibiotic are present, the
incidence is far lower than would be expected with rifampin, and it
is thought that the drug may retain efﬁcacy against isolates with
higher minimum inhibitory concentration (MIC) values due to high
concentrations achieved in the feces.70,74Published clinical evi-
dence of rifaximin use includes three case series, a prospective
pilot study, and one randomized controlled trial. Johnson et al.
reported no recurrence of CDI in seven of eight women
administered rifaximin following their last treatment with
vancomycin, a method termed a rifaximin ‘chaser’; the one patient
who exhibited recurrence responded to a second treatment course
of rifaximin, though rifaximin-resistant C. difﬁcile was isolated
from this patient after her second treatment course.75 Garey et al.
reported success of a rifaximin taper in symptomatic, hospitalized
patients.76 More recently, a series of three liver transplant patients
with recurrent diarrhea experienced resolution of symptoms
within 36–48 h of initiation of rifaximin after failure of both
metronidazole and vancomycin.77 Basu et al. also reported
eradication of CDI in 64% of an intent-to-treat population of 25
patients who received rifaximin after failure of metronidazole
therapy.78 The most common dosages of rifaximin range from 400
to 800 mg daily in two to three divided doses for 2 weeks; though
some studies report extended durations of up to 28 days. Adverse
reactions of rifaximin may include peripheral edema, dizziness and
fatigue, ascites, and nausea, though it is generally well tolerated.75–
78
The use of rifaximin as a ‘chaser’ following standard antibiotic
treatment is a potential treatment option in patients with
refractory or recurrent CDI.
3.10.3. Nitazoxanide
Nitazoxanide is an older agent that is effective in the treatment
of parasitic gastrointestinal infections such as cryptosporidiosis,
particularly in immunocompromised patients.79 Nitazoxanide
blocks anaerobic metabolism of eukaryotes and has been found
to inhibit C. difﬁcile in vitro and at low concentrations, including
strains resistant to metronidazole.80,81 In a hamster model,
nitazoxanide was found to have MICs and minimum bactericidal
concentrations (MBCs) against 15 toxigenic strains of C. difﬁcile
that were comparable to those of vancomycin or metronidazole.82
Musher et al. conducted a prospective, randomized, double-blind
study to compare nitazoxanide (500 mg twice daily for 7 or 10
days) to metronidazole in hospitalized patients and found
nitazoxanide and metronidazole to have comparable efﬁcacies.
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rate in patients who failed metronidazole therapy.83Most recently,
Musher et al. conducted a prospective, randomized controlled trial
comparing 10-day therapy with vancomycin or nitazoxanide, and
the two were found to have similar end-of-therapy response rates
(87%, 20 of 23 vs. 94%, 17 of 18, respectively).84 The adverse effect
proﬁle of nitazoxanide appears to be mild, mainly including
headache and gastrointestinal complaints.
While further studies of nitazoxanide will be needed, this agent
appears safe and effective as an option for recurrent or refractory
disease. This also offers an additional option in select patients for
initial treatment of CDI.
3.10.4. Tigecycline
Tigecycline, approved for the treatment of skin and skin
structure infections as well as community-acquired pneumonia,
has emerging data supporting its use in CDI. Tigecycline is
associated with a low risk of CDI, and recent in vitro studies,
primarily in Europe, have revealed that among multidrug-resistant
isolates of Clostridium, all were susceptible to tigecycline.85
Tigecycline has also been found to reach fecal concentrations high
enough to reduce intestinal microﬂora without inducing C. difﬁcile
cytotoxin production.
There have been no prospective clinical trials of tigecycline for
the treatment of CDI; however, a case series did report successful
outcomes with no recurrences of CDI in a group of patients in
whom tigecycline was used for salvage therapy.86 One published
case report discussed the success of tigecycline for the treatment of
CDI refractory to metronidazole and vancomycin, while another
published case reported failure of tigecycline in combination with
vancomycin and metronidazole in a patient with severe CDI.87,88
Standard dosing of tigecycline is a 100 mg loading dose followed by
50 mg intravenously every 12 h, with the most common adverse
effects being nausea and vomiting.86,89
While tigecycline has not been extensively studied in vivo for
the treatment of CDI, it may be a promising treatment option in
patients with refractory, recurrent CDI resistant to standard
treatment options. Tigecycline should also be considered a low-
risk antibiotic for causing CDI.
3.10.5. Linezolid
Linezolid, a member of the oxazolidinone class of antibiotics,
was found to have in vitro activity against C. difﬁcile.90,91
Approximately 12–23% of linezolid is excreted unchanged in the
stool and a limited impact on normal gut ﬂora was noted in a single
study.91,92 A single case report indicated failure of IV linezolid in
CDI, and Zabel and Worm reported a case of linezolid contributing
to fatal C. difﬁcile colitis.93,94 No speciﬁc dosing regimen of linezolid
for C. difﬁcile can be recommended at this time, as studies have
mainly been in vitro; the typical dosing range of linezolid is 600 mg
every 12 h. In addition, diarrhea can be a substantial adverse effect
of linezolid.93
At this time, the inconclusive data surrounding linezolid
prevent recommendation as an option for the treatment of C.
difﬁcile disease. Linezolid may be considered a low-risk antibiotic
for contributing to CDI.
3.11. Antimicrobials under development for the treatment of C.
difﬁcile disease
3.11.1. Ramoplanin
Ramoplanin is an antimicrobial compound with in vitro activity
against C. difﬁcile and is currently under investigation for treatment
of enterococcal infections and CDI.95,96 Ramoplanin inhibits cell
wall synthesis by acting at the level of lipid intermediate formation
against C. difﬁcile and was found to be as effective as vancomycin inhamster models.96 A phase II trial of ramoplanin has revealed
equivalence to vancomycin for the treatment of C. difﬁcile colitis at
doses of 200 or 400 mg administered twice daily for 10 days.96
Adverse effects of ramoplanin were also found to be comparable to
vancomycin and most commonly included gastrointestinal com-
plaints.96
Though ramoplanin is currently not approved by the FDA, it
may be a promising emerging treatment alternative to vancomycin
for initial treatment of CDI.
3.11.2. Fidaxomicin
Fidaxomicin is a novel, narrow-spectrum macrocyclic antibiotic
agent that has shown selective in vitro activity against C. difﬁcile.
Fidaxomicin differs from vancomycin and metronidazole in that it
exhibits little to no activity against the normal gastrointestinal
ﬂora, eliminating C. difﬁcile while allowing recovery of the
protective normal ﬂora.97 Fidaxomicin appears to achieve high
concentrations in the feces compared to low concentrations in the
plasma, preferential in the treatment of CDI. Preliminary clinical
trials indicate that ﬁdaxomicin may be an effective option for the
treatment of mild-to-moderate CDI, comparable to vancomycin
and resulting in fewer recurrences.98,99 Currently, two phase III
clinical trials of ﬁdaxomicin indicate that among 1105 patients
with CDI, those treated with ﬁdaxomicin experienced similar cure
rates to those patients treated with vancomycin, and the
ﬁdaxomicin group experienced 47% fewer recurrences. Among
128 patients with recurrent CDI, 35.5% receiving vancomycin
experienced yet another recurrence as opposed to only 19.7% in the
ﬁdaxomicin group. Fidaxomicin has also shown efﬁcacy against
the hypervirulent BI/NAP1/027 strain of C. difﬁcile.100,101 The
adverse effect proﬁle of ﬁdaxomicin may include gastrointestinal
complaints, generalized symptoms including fever, chills, and
fatigue; however, adverse effects in clinical trials have been
comparable to vancomycin.101,102
The manufacturer recently reported a New Drug Application
was accepted by the FDA with a goal date for priority review of May
31, 2011.103 Fidaxomicin appears to be an effective and safe
alternative to standard therapy for the treatment of CDI, while also
reducing the rate of relapse.
4. Conclusions
The incidence and hospitalizations due to C. difﬁcile infection
and disease have grown at an alarming rate since C. difﬁcile was
ﬁrst linked to human disease in 1977, due in part to the increased
use of broad-spectrum antibiotics. Patients who develop an initial
C. difﬁcile infection and are treated with metronidazole or
vancomycin often enter remission only to develop recurrent
infections that become increasingly difﬁcult to treat with further
antibiotic therapy due to suppression of normal gut ﬂora. While
judicious use of antibiotics and implementation of proper infection
control procedures will hopefully reduce the incidence of C.
difﬁcile-associated disease, there are promising alternative and
adjunctive therapies for the prevention and treatment of C. difﬁcile
on the horizon.
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